Ticker Details
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
IPO Date:	May 28, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$47.46B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.75 | 2.19%
Avg Daily Range (30 D):	$6.22 | 1.50%
Avg Daily Range (90 D):	$6.62 | 1.50%

Institutional Daily Volume
Avg Daily Volume:	.55M
Avg Daily Volume (30 D):	1.22M
Avg Daily Volume (90 D):	1M

Trade Size
Avg Trade Size (Sh.):	76
Avg Trade Size (Sh.) (30 D):	35
Avg Trade Size (Sh.) (90 D):	33

Institutional Trades
Total Institutional Trades:	10,719
Avg Institutional Trade:	$7.8M
Avg Institutional Trade (30 D):	$67.49M
Avg Institutional Trade (90 D):	$45.13M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$13.9M
Avg Closing Trade (30 D):	$128.36M
Avg Closing Trade (90 D):	$84.17M
Avg Closing Volume:	84.46K

News

Jan 12, 2026 @ 6:33 PM Alnylam Lays Out 2030 Vision, Bets On TTR Leadersh... Source: Vandana Singh

Jan 7, 2026 @ 10:00 AM Scenic Biotech Enters License and Research Agreeme... Source: Unknown

Jan 2, 2026 @ 8:13 AM This AI Infrastructure Stock Is 'Most Likely' To B... Source: Vishaal Sanjay

Dec 13, 2025 @ 1:00 AM Annual Changes to the Nasdaq-100 Index® Source: Nasdaq

Dec 7, 2025 @ 7:25 AM Is Alnylam Pharmaceuticals a Millionaire Maker? Source: Keith Speights

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$.33	$1.91	$-.51
Diluted EPS	$.3	$1.84	$-.51
Revenue	$3.21B	$1.25B	$773.69M
Gross Profit	$2.7B	$1.05B	$631.66M
Net Income / Loss	$43.57M	$251.08M	$-66.28M
Operating Income / Loss	$264.7M	$367.98M	$-16.2M
Cost of Revenue	$512.09M	$197.23M	$142.03M
Net Cash Flow	$390.3M	$376.94M	$93.61M
PE Ratio	1,171.97